Innovation Pharmaceuticals Inc. - FORM 10-K - EX-32.1 - CERTIFICATION - September 8, 2017

Attached files

file filename
10-K - FORM 10-K - Innovation Pharmaceuticals Inc.ipix_10k.htm
EX-32.2 - CERTIFICATION - Innovation Pharmaceuticals Inc.ipix_ex322.htm
EX-31.2 - CERTIFICATION - Innovation Pharmaceuticals Inc.ipix_ex312.htm
EX-31.1 - CERTIFICATION - Innovation Pharmaceuticals Inc.ipix_ex311.htm
EX-23.1 - CONSENT - Innovation Pharmaceuticals Inc.ipix_ex231.htm
EX-10.16 - FORM OF NON-QUALIFIED STOCK OPTION AGREEMENT - Innovation Pharmaceuticals Inc.ipix_ex1016.htm
EX-10.7 - REGISTRATION RIGHTS AGREEMENT - Innovation Pharmaceuticals Inc.ipix_ex107.htm
EX-10.6 - COMMON STOCK PURCHASE AGREEMENT - Innovation Pharmaceuticals Inc.ipix_ex106.htm
EX-5.1 - OPINION OF GARY R. HENRIE, ESQ. - Innovation Pharmaceuticals Inc.ipix_ex51.htm
EX-3.2 - AMENDED AND RESTATED BYLAWS - Innovation Pharmaceuticals Inc.ipix_ex32.htm

EXHIBIT 32.1

 

Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

 

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officer of Innovation Pharmaceuticals Inc., a Nevada corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:

 

·

The Annual Report on Form 10-K for the fiscal year ended June 30, 2017 of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

·

The information contained in the Annual Report on Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

Dated: September 8, 2017

By:

/s/ Krishna Menon

Krishna Menon

President of Research and Director

Stock widget

Investing forum

Innovation Pharmaceuticals Inc. Reports